Lipocine
LPCN
44 hedge funds and large institutions have $16.3M invested in Lipocine in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 4 closing their positions.
809% more call options, than puts
Call options by funds: $1.77M | Put options by funds: $195K
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
55% more capital invested
Capital invested by funds: $10.5M → $16.3M (+$5.76M)
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
13% more funds holding
Funds holding: 39 → 44 (+5)
0.08% more ownership
Funds ownership: 0.71% → 0.79% (+0.08%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
+$810K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$693K |
| 3 |
Two Sigma Investments
New York
|
+$317K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$218K |
| 5 |
Two Sigma Advisers
New York
|
+$110K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$437K |
| 2 |
Morgan Stanley
New York
|
-$228K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$166K |
| 4 |
BlackRock
New York
|
-$36.7K |
| 5 |
HF
HRT Financial
New York
|
-$23K |
LPCN Hedge Fund Activity: Q1 2022 in Review
44 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2022, worth a combined $16.3M — up 55% from $10.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new LPCN positions and 4 closed out — a net gain of 5 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $810K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $437K sold.
- 44 institutional investors held Lipocine (LPCN) as of Q1 2022, up from 39 in Q4 2021.
- Funds reported $16.3M of Lipocine stock for Q1 2022, up 55% quarter-over-quarter.
- 9 funds opened new Lipocine positions in Q1 2022 and 4 closed out, a net change of +5 holders.
- The largest Lipocine buyer in Q1 2022 was EAM Investors, an estimated $810K added.
- The largest Lipocine seller in Q1 2022 was GSA Capital Partners, an estimated $437K sold.
Based on aggregated 13F filings for Q1 2022.